Bayer to provide brand-new Kerendia ™ (finerenone) information from thorough scientific trial program throughout a broad variety of clients with persistent kidney illness and type 2 diabetes

Berlin, June 3, 2022, – Bayer will provide brand-new kidney and cardiovascular information from the extensive Kerendia ™ (finerenone) medical trial program at the 2022 American Diabetes Association (ADA) 82^nd Scientific Sessions. This brand-new information will consist of more insights from FIDELITY, consisting of late-breaking information from a brand-new post-hoc analysis, along with retrospective findings from FIDELIO-DKD and FIGARO-DKD. The prespecified pooled analysis FIDELITY, consisting of the Phase III research studies FIDELIO-DKD and FIGARO-DKD, makes up the biggest Phase III cardiorenal results scientific trial program examining cardiorenal results in more than 13,000 clients with CKD and T2D.

Kerendia FIDELITY research study information:

Information from a brand-new post-hoc analysis from FIDELITY will examine the result of finerenone by standard HbA1c classifications, HbA1c irregularity, and diabetes period in clients with persistent kidney illness (CKD) and type 2 diabetes (T2D). In spite of well-controlled blood sugar levels and high blood pressure, numerous clients with CKD and diabetes still advance to loss of kidney function. New techniques are required to avoid more end-organ damage and sluggish client’s rate of decrease in kidney function.

· Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes
o 16-LB – Late Breaking Poster Session
o June 5, 2022; 12:00 – 1:00 pm (CT)/ 7:00 – 8:00 pm (CEST)
In addition, a brand-new subgroup analysis of FIDELITY will exist, assessing the impacts of finerenone on kidney and cardiovascular (CV) results by utilize of glucagon-like peptide-1 receptor agonists (GLP-1RA) at standard. This analysis includes a bigger population consisting of clients with earlier phases of CKD than was consisted of in the formerly provided subgroup analysis by GLP-1RA usage from the FIDELIO-DKD trial.

· Finerenone in Patients throughout the Spectrum of CKD and T2D by GLP-1RA Use
o 22-OR – Oral Presentation
o June 3, 2022; 5:30 – 5:45 pm (CT)/ June 4, 2022; 12:30 – 12:45 am (CEST)

Finerenone FIDELIO-DKD & & FIGARO-DKD research study information:

Bayer will provide brand-new exploratory information from FIDELIO-DKD and FIGARO-DKD, examining the impacts of finer